Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Kyprolis Advancing, Millennium Stakes Faith In Oral Velcade Successor

Executive Summary

Takeda/Millennium’s oral weekly proteasome inhibitor MLN9708 looked effective with a mild neuropathy profile in a new myeloma study presented at the American Society of Hematology meeting, and Takeda has committed to large Phase III trials. There’s no time to lose – mid-stage studies presented for Onyx’ rival Kyprolis, currently approved for relapsed myeloma, support moving that drug to the frontline.

You may also be interested in...



Takeda’s Weekly Oral Proteasome Inhibitor Ixazomib Passes First Pivotal Test

Company plans to submit data from positive TOURMALINE-MM1 study of Velcade follow-on ixazomib in relapsed myeloma to regulators; drug set for 2015 filing.

Takeda’s Weekly Oral Proteasome Inhibitor Ixazomib Passes First Pivotal Test

Company plans to submit data from positive TOURMALINE-MM1 study of Velcade follow-on ixazomib in relapsed myeloma to regulators; drug set for 2015 filing.

Onyx Starts Acquisition Process; Price And Competition To Come Into Play

The fast-growing biotech is soliciting bids, after a rejected Amgen offer and additional third party interest. Wall Street is scrambling to determine how to value Onyx and who the bidders could be.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel